LivingGLP1
Study S001760

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT02420262
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
NONE
Status
COMPLETED
Enrollment
506
Start
2015-07-26
Primary completion
2016-10-05
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:insulin degludec/liraglutide; DRUG:insulin glargine; DRUG:insulin aspart
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2014-003621-18; OTHER:U1111-1160-6923; REGISTRY:REec-2015-1682; NIH:2014

Registered primary outcomes

  • Change in HbA1c (Glycosylated Haemoglobin) [Week 0, Week 26]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0014471The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK, Journal of diabetes science and technology
2021Randomized trialPMID 32107930DOIcites ClinicalTrials.gov:NCT02420262; registry reference DERIVED:32107930
R0014338Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L, Diabetic medicine : a journal of the British Diabetic Association
2020Nonrandomized studyPMID 31705547DOIcites ClinicalTrials.gov:NCT02420262; registry reference DERIVED:31705547
R0018886Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ, Journal of managed care & specialty pharmacy
2020Randomized trialPMID 31856636DOIcites ClinicalTrials.gov:NCT02420262
R0022785Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.
Billings LK, ClinicoEconomics and outcomes research : CEOR
2019OtherPMID 30962697DOIcites ClinicalTrials.gov:NCT02420262
R0018041Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK, Diabetes care
2018Randomized trialPMID 29483185DOIcites ClinicalTrials.gov:NCT02420262; registry reference RESULT:29483185
R0049343Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
Liana K. Billings, Canadian Journal of Diabetes
2018Other trialDOIcites ClinicalTrials.gov:NCT02420262